Human CellExp UPA, human recombinant protein
Urokinase, PLAU, ATF, UPA, URK, u-PA,BDPLT5,QPD
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P00749 |
---|---|
Calculated MW | This protein is fused with 6×His tag at the C-terminus, has a calculated MW of 45 kDa. The predicted N-terminus is Ser21, Ile179 & Lys156 . DTT-reduced Protein migrates as three bands corresponding to the long α chain, β chain and unprocessed full-length chain with the molecular mass of 18 kDa, 32 kDa and 50 kDa respectively due to glycosylation and cleavage. |
Gene ID | 5328 |
---|---|
Gene Symbol | uPA |
Other Names | Urokinase, PLAU, ATF, UPA, URK, u-PA,BDPLT5,QPD |
Gene Source | Human |
Source | HEK 293 cells |
Assay&Purity | SDS-PAGE; ≥95% |
Assay2&Purity2 | HPLC; |
Recombinant | Yes |
Target/Specificity | UPA |
Application Notes | Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C. |
Format | Lyophilized powder |
Storage | -20°C; Lyophilized from 0.22 µm filtered solution in HEPES, NaCl and CaCl2. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Urokinase - type plasminogen activator also known as PLAU and UPA, a serine protease with extremely limited substrate specificity, cleaving the sequence Cys – Pro – Gly - Arg560 - Val561 – Val – Gly – Gly – Cys in plasminogen to form plasmin. uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium. The human PLAU is initially synthesized as 431 amino acid precursor with a N-terminal signal peptide (20 residues). The single chain molecule is processed into a disulfide-linked two-chain molecule of different molecular weights. Two forms of the A chain exist, starting at Ser21 (the long form) and Lys156 (the short form). The long and short A chains are unique to the high and low molecular weight forms, respectively. The long A chain contains an EGF-like domain, responsible for binding of the PLAU receptor. The B chain corresponds to the catalytic domain.
References
Holmes W.E.,et al.Biotechnology (N.Y.) 3:923-929(1985).
Jacobs P.,et al.DNA 4:139-146(1985).
Nagai M.,et al.Gene 36:183-188(1985).
Riccio A.,et al.Nucleic Acids Res. 13:2759-2771(1985).
Kalnine N.,et al.Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.